scholarly journals Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections

2017 ◽  
Vol 12 (1) ◽  
Author(s):  
Helmut H. Albrecht ◽  
Peter V. Dicpinigaitis ◽  
Eric P. Guenin
Keyword(s):  
Respiratory Tract ◽  
Chronic Bronchitis ◽  
Respiratory Tract Infections ◽  
Upper Respiratory Tract Infections ◽  
Upper Respiratory Tract ◽  
Upper Respiratory ◽  
Tract Infections

scholarly journals A role of oropharyngeal microbiota in developing acute and chronic diseases of the upper respiratory tract

2020 ◽  
Vol 10 (2) ◽  
pp. 359-367
Author(s):  
I. I. Ababii ◽  
L. A. Danilov ◽  
M. K. Maniuc ◽  
P. I. Ababii ◽  
S. S. Ghinda ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Chronic Tonsillitis ◽  
Upper Respiratory Tract Infections ◽  
Control Group ◽  
Healthy Children ◽  
Upper Respiratory Tract ◽  
Upper Respiratory ◽  
Tract Infections

Currently, a rise in incidence of polyethological inflammation of the upper respiratory tract mucosa paralleled by altered resident and transient microbiota displaying in many cases increased antibiotic resistance has been noted. Opportunistic microbes play a major role in developing inflammatory process in Pirogov–Waldeyer’s ring. An inflammatory process occurring in the tonsillar lymphatic tissue results in host systemic complications. Fighting against acute and chronic infections of the upper respiratory tract holds the main task in pediatric otorhinolaryngology, as they can consequently elicit the cardiovascular, genitourinary and musculoskeletal complications. The results of studies examining this issue remain very contradictory, which accounted for a need to conduct our study on the territory of Moldova featured with mixed climatic conditions. Here, we wanted to study a role of microbial factor in etiopathogenesis of chronic tonsillitis in children. Bacteriological microbiota data for superficial palatine tonsils were obtained form 608 children subdivided into 5 groups: group I — 333 children with compensated chronic tonsillitis; group II — 87 children with decompensated chronic tonsillitis; group III — 91 children with acute upper respiratory tract infections (comparison group); group IV — 48 children with acute upper respiratory tract infections treated with antibiotic therapy; group V — 49 apparently healthy children (control group). It was found that β-hemolytic streptococcus exerting high sensitivity to virtually all antibiotics groups was detected in 17.4% of children with acute tonsilar inflammatory processes and decompensated defense in the lymphatic pharyngeal ring compared to 3.5% in control group. Streptococcus pneumoniae was isolated in all study groups ranging within 4.8–21.7%, including 14% in apparently healthy children characterized by reduced antibiotics sensitivity. The data obtained suggest that sickly children with acute and chronic upper respiratory tract infections constitute a risk group for developing somatic diseases. The high incidence of Streptococcus pneumoniae indicates a need for performing immunoprophylaxis, use of therapeutic vaccination as a up-to-date, combined approach in treatment of such pediatric cohort.

scholarly journals Role of respiratory viruses in infants less than six months of age with upper respiratory tract infections

2017 ◽  
Vol 39 (3) ◽  
pp. 564-569
Author(s):  
Eda Karadağ Öncel ◽  
Demet Başer ◽  
Ayça Kömürlüoğlu ◽  
Meral Ciblak ◽  
Yasemin Özsürekçi ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Respiratory Viruses ◽  
Upper Respiratory Tract Infections ◽  
Upper Respiratory Tract ◽  
Upper Respiratory ◽  
Tract Infections

scholarly journals Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections

2017 ◽  
Vol 12 ◽  
Author(s):  
Helmut H. Albrecht ◽  
Peter V. Dicpinigaitis ◽  
Eric P. Guenin
Keyword(s):  
Respiratory Tract ◽  
Chronic Bronchitis ◽  
Respiratory Tract Infections ◽  
Quality Data ◽  
Upper Respiratory Tract Infections ◽  
Upper Respiratory Tract ◽  
Mucus Hypersecretion ◽  
Upper Respiratory ◽  
Tract Infections ◽  
Respiratory Conditions

Guaifenesin, a mucoactive drug, acts by loosening mucus in the airways and making coughs more productive. It is used for relief of wet cough and chest congestion due to the common cold, and remains the only legally marketed expectorant in the US (per OTC Monograph). An ingredient in numerous over-the-counter (OTC) cough/cold medications, guaifenesin has a secondary indication for use in stable chronic bronchitis (professional indication). Clinical pharmacology and patient studies support the clinical utility of guaifenesin in respiratory conditions where mucus hypersecretion is prevalent: acute upper respiratory tract infections (URTIs), stable chronic bronchitis, and possibly rhinosinusitis. Guaifenesin has a well-established and favorable safety and tolerability profile in adult and pediatric populations. Its dosing range (200–400 mg 4-hourly, up to 6× daily) allows flexible dose titration to allow an increase of plasma concentrations. Multiple daily doses are needed to maintain 24-h therapeutic effect with immediaterelease formulations. Extended-release guaifenesin tablet formulations are available, providing convenience with 12-hourly dosing and portability compared to liquids. Guaifenesin is considered as a safe and effective expectorant for the treatment of mucus-related symptoms in acute URTIs and stable chronic bronchitis. Its clinical efficacy has been demonstrated most widely in chronic respiratory conditions, where excess mucus production and cough are more stable symptoms. Progress is being made to establish clinical models and measures that are more appropriate for studying symptomatic relief with guaifenesin in acute respiratory infections. This will help generate the up-to-date and high-quality data needed to optimize guaifenesin’s effectiveness in established uses, and in new respiratory indications associated with mucus hypersecretion.

Sign in / Sign up

Export Citation Format

Share Document